KAEF Stock Overview
Engages in the manufacturing and sale of pharmaceutical products in Indonesia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
PT Kimia Farma Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp615.00 |
| 52 Week High | Rp1,935.00 |
| 52 Week Low | Rp535.00 |
| Beta | 0.21 |
| 11 Month Change | 4.24% |
| 3 Month Change | -16.33% |
| 1 Year Change | -26.35% |
| 33 Year Change | -76.88% |
| 5 Year Change | -80.78% |
| Change since IPO | 192.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| KAEF | ID Pharmaceuticals | ID Market | |
|---|---|---|---|
| 7D | -3.1% | 0.4% | -1.2% |
| 1Y | -26.3% | -18.1% | 9.4% |
Return vs Industry: KAEF underperformed the ID Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: KAEF underperformed the ID Market which returned 9.4% over the past year.
Price Volatility
| KAEF volatility | |
|---|---|
| KAEF Average Weekly Movement | 7.8% |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in ID Market | 12.8% |
| 10% least volatile stocks in ID Market | 2.9% |
Stable Share Price: KAEF's share price has been volatile over the past 3 months.
Volatility Over Time: KAEF's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1817 | 11,181 | David Utama | kimiafarma.co.id |
PT Kimia Farma Tbk engages in the manufacturing and sale of pharmaceutical products in Indonesia. It also provides generic, ethical, license and narcotic medicines, over the counter medicines, raw materials, medicines, medical devices, and cosmetic products, as well as rapid test diagnostic tools. In addition, the company is involved manufacturing and marketing of pharmaceutical raw materials and active pharmaceutical ingredients; health foods and effervescent tablets; quinine salt and related derivatives; and castor oil and edible oil.
PT Kimia Farma Tbk Fundamentals Summary
| KAEF fundamental statistics | |
|---|---|
| Market cap | Rp3.42t |
| Earnings (TTM) | -Rp1.55t |
| Revenue (TTM) | Rp10.20t |
0.3x
P/S Ratio-2.2x
P/E RatioIs KAEF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KAEF income statement (TTM) | |
|---|---|
| Revenue | Rp10.20t |
| Cost of Revenue | Rp7.45t |
| Gross Profit | Rp2.75t |
| Other Expenses | Rp4.30t |
| Earnings | -Rp1.55t |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -278.57 |
| Gross Margin | 26.93% |
| Net Profit Margin | -15.21% |
| Debt/Equity Ratio | 126.8% |
How did KAEF perform over the long term?
See historical performance and comparison